{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:53Z","timestamp":1792264973515,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ISRM\/12(22)\/2020"],"award-info":[{"award-number":["ISRM\/12(22)\/2020"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["27(0368)\/20\/EMR-II"],"award-info":[{"award-number":["27(0368)\/20\/EMR-II"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bbrc.2023.02.075","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T16:02:56Z","timestamp":1678204976000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Therapeutic targeting of Huntington's disease: Molecular and clinical approaches"],"prefix":"10.1016","volume":"655","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4792","authenticated-orcid":false,"given":"Dhiraj","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-3253","authenticated-orcid":false,"given":"Gulam Mustafa","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asimul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3663-4940","authenticated-orcid":false,"given":"Md. Imtaiyaz","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.02.075_bib1","series-title":"On Chorea","author":"Huntington","year":"1872"},{"issue":"15005","key":"10.1016\/j.bbrc.2023.02.075_bib2","first-page":"5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.bbrc.2023.02.075_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington's disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib4","first-page":"1","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"461","key":"10.1016\/j.bbrc.2023.02.075_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bbrc.2023.02.075_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"24","key":"10.1016\/j.bbrc.2023.02.075_bib7","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbrc.2023.02.075_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","article-title":"Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2023.02.075_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.omtn.2019.12.012","article-title":"Universal RNAi triggers for the specific inhibition of mutant huntingtin, atrophin-1, ataxin-3, and ataxin-7 expression","volume":"19","author":"Kotowska-Zimmer","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7858","key":"10.1016\/j.bbrc.2023.02.075_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/d41586-021-01177-7","article-title":"Failure of genetic therapies for Huntington's devastates community","volume":"593","author":"Kwon","year":"2021","journal-title":"Nature"},{"issue":"R1","key":"10.1016\/j.bbrc.2023.02.075_bib11","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","article-title":"Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia","volume":"25","author":"Keiser","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.bbrc.2023.02.075_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.bbrc.2023.02.075_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2017.199","article-title":"Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease","volume":"29","author":"Pfister","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"20","key":"10.1016\/j.bbrc.2023.02.075_bib14","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.bbrc.2023.02.075_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J.\u00a0Clin. Investig."},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in\u00a0vitro and in\u00a0vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.bbrc.2023.02.075_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem Cell Rep."},{"issue":"45","key":"10.1016\/j.bbrc.2023.02.075_bib18","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7","key":"10.1016\/j.bbrc.2023.02.075_bib19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bbrc.2023.02.075_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3727\/096368916X690863","article-title":"Allele-specific reduction of the mutant huntingtin allele using transcription activator-like Effectors in human Huntington's disease fibroblasts","volume":"25","author":"Fink","year":"2016","journal-title":"Cell Transplant."},{"issue":"11","key":"10.1016\/j.bbrc.2023.02.075_bib21","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/hmg\/ddu010","article-title":"A\u00a0potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease","volume":"23","author":"Smith","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.bbrc.2023.02.075_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JHD-120029","article-title":"PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6\/2 mouse model of Huntington's disease","volume":"1","author":"Cherny","year":"2012","journal-title":"J.\u00a0Huntingtons Dis."},{"issue":"3","key":"10.1016\/j.bbrc.2023.02.075_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","article-title":"An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease","volume":"79","author":"S\u00fcssmuth","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","article-title":"Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"14","year":"2015","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.bbrc.2023.02.075_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.bbrc.2023.02.075_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JHD-199003","article-title":"Huntington's disease clinical trials corner: June 2019","volume":"8","author":"Rodrigues","year":"2019","journal-title":"J.\u00a0Huntingtons Dis."},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JHD-189001","article-title":"Huntington's disease clinical trials corner: February 2018","volume":"7","author":"Rodrigues","year":"2018","journal-title":"J.\u00a0Huntingtons Dis."},{"issue":"8","key":"10.1016\/j.bbrc.2023.02.075_bib28","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41591-021-01467-7","article-title":"Record number of gene-therapy trials, despite setbacks","volume":"27","author":"Arnold","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2023.02.075_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.bbrc.2023.02.075_bib30","first-page":"12","article-title":"Pridopidine for the improvement of motor function in patients with Huntington's disease: a systematic review and meta-analysis of randomized controlled trials","author":"Chen","year":"2021","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.bbrc.2023.02.075_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/d41573-019-00018-7","article-title":"Pioneering antisense drug heads into pivotal trials for Huntington disease","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2023.02.075_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymeth.2017.08.017","article-title":"Stem cell transplantation for Huntington's diseases","volume":"133","author":"Choi","year":"2018","journal-title":"Methods"},{"issue":"3","key":"10.1016\/j.bbrc.2023.02.075_bib33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41380-018-0021-9","article-title":"Are immunotherapies for Huntington's disease a realistic option?","volume":"24","author":"Denis","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.bbrc.2023.02.075_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/DDDT.S138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease","volume":"12","author":"Dean","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"11","key":"10.1016\/j.bbrc.2023.02.075_bib35","article-title":"Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington's disease patients-A randomized phase 2 clinical trial","volume":"9","author":"Brownstein","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.bbrc.2023.02.075_bib36","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1016\/j.euroneuro.2021.10.399","article-title":"P.0426 Proof-of-concept study testing SOM3355 for the treatment of chorea symptoms in Huntington's disease","volume":"53","author":"Gamez","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.bbrc.2023.02.075_bib37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","article-title":"Triheptanoin improves brain energy metabolism in patients with Huntington disease","volume":"84","author":"Adanyeguh","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.bbrc.2023.02.075_bib38","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1172\/JCI70911","article-title":"Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration","volume":"123","author":"Guo","year":"2013","journal-title":"J.\u00a0Clin. Investig."},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/srep29789","article-title":"VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease","volume":"6","author":"D\u00edaz-Alonso","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbrc.2023.02.075_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib41","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41467-022-28653-6","article-title":"An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion","volume":"13","author":"Keller","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2023.02.075_bib42","article-title":"An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J\u00a0Neurodegener Dis"},{"issue":"1","key":"10.1016\/j.bbrc.2023.02.075_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27157-z","article-title":"Small molecule splicing modifiers with systemic HTT-lowering activity","volume":"12","author":"Bhattacharyya","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bbrc.2023.02.075_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.121","article-title":"An in\u00a0vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity","volume":"3","author":"Cisbani","year":"2012","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bbrc.2023.02.075_bib45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.26006","article-title":"Animal models of Huntington's disease for translation to the clinic: best practices","volume":"29","author":"Menalled","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbrc.2023.02.075_bib46","article-title":"The challenge in translating basic research discoveries to treatment of Huntington disease","volume":"2","author":"Mochly-Rosen","year":"2014","journal-title":"Rare Dis."},{"issue":"4","key":"10.1016\/j.bbrc.2023.02.075_bib47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/nmt.12.34","article-title":"Monitoring Huntington's disease progression through preclinical and early stages","volume":"2","author":"Tang","year":"2012","journal-title":"Neurodegener. Dis. Manag."},{"issue":"12","key":"10.1016\/j.bbrc.2023.02.075_bib48","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/mds.28222","article-title":"Clinical outcomes and selection criteria for prodromal Huntington's disease trials","volume":"35","author":"Langbehn","year":"2020","journal-title":"Mov. Disord."},{"issue":"7853","key":"10.1016\/j.bbrc.2023.02.075_bib49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/d41586-021-00870-x","article-title":"Genetic therapies offer new hope against incurable brain diseases","volume":"592","author":"Kwon","year":"2021","journal-title":"Nature"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23002619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23002619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:27:28Z","timestamp":1757766448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23002619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":49,"alternative-id":["S0006291X23002619"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.02.075","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of Huntington's disease: Molecular and clinical approaches","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.02.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}